Literature DB >> 6097324

Characterization of prolactin receptors in human breast cancer.

J P Peyrat, J Djiane, P A Kelly, B Vandewalle, J Bonneterre, A Demaille.   

Abstract

In order to perform measurement of PRL binding and to improve the knowledge of pathophysiological variations in human mammary cancers, we have investigated in detail the binding characteristics of PRL in membranes prepared from these tumors. The optimization of the assay requires the selection of membranous components of light density (less than 1.17); the tracer could be either 125I-PRL after affinity purification on PRL receptors or 125I-hGH without a purification step. It is favorable to utilize a high amount of protein and 200 000 cpm (2 ng) of tracer. Demonstration of the presence of receptors for PRL with a high affinity (Kd= 3 X 10(-10) M) in breast cancer is presented. The hormonal specificity of these receptors is studied: only lactogenic hormones (hGH, oPRL, hPRL, and hPL) are able to compete for binding of 125I-hPRL whereas bGH or insulin are without effect. Considering the known effect of PRL on cell multiplication, it is tempting to suggest that this hormone could have a crucial role in the development of breast tumor in humans and that therapies which would suppress secretion of PRL and GH could be beneficial.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6097324     DOI: 10.1007/bf01806039

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

1.  Bromocriptine in the treatment of advanced breast cancer.

Authors:  A Barrett; L Morgan; P R Raggatt; J R Hobbs
Journal:  Clin Oncol       Date:  1976-12

2.  In vitro stimulation of human breast tissue by human prolactin.

Authors:  W G Dilley; S J Kister
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

3.  Clinical trial of 2-Br- -ergocryptine (CB154) in advanced breast cancer.

Authors: 
Journal:  Eur J Cancer       Date:  1972-04       Impact factor: 9.162

4.  Solubilization and purification of a prolactin receptor from the rabbit mammary gland.

Authors:  R P Shiu; H G Friesen
Journal:  J Biol Chem       Date:  1974-12-25       Impact factor: 5.157

5.  Correlation between prolactin-receptor interaction, down-regulation of receptors, and stimulation of casein and deoxyribonucleic acid biosynthesis in rabbit mammary gland explants.

Authors:  J Djiane; L M Houdebine; P A Kelly
Journal:  Endocrinology       Date:  1982-03       Impact factor: 4.736

6.  Prolactin receptors in human breast cancer.

Authors:  J Bonneterre; J P Peyrat; B Vandewalle; R Beuscart; M C Vie; P Cappelaere
Journal:  Eur J Cancer Clin Oncol       Date:  1982-11

7.  Prolactin binding by human mammary carcinoma: relationship to estrogen receptor protein concentration and patient age.

Authors:  B Rae-Venter; T Nemoto; S L Schneider; T L Dao
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

8.  Prolactin and murine mammary tumorigenesis: a review.

Authors:  C W Welsch; H Nagasawa
Journal:  Cancer Res       Date:  1977-04       Impact factor: 12.701

9.  Physiological concentrations of prolactin can promote the growth of human breast tumor cells in culture.

Authors:  W B Malarkey; M Kennedy; L E Allred; G Milo
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

10.  Prolactin receptor in human mammary carcinoma.

Authors:  R Di Carlo; G Muccioli
Journal:  Tumori       Date:  1979-12-31
View more
  2 in total

1.  Establishment and characterization of a new cell line (VHB-1) derived from a primary breast carcinoma.

Authors:  B Vandewalle; M Collyn d'Hooghe; J B Savary; M O Vilain; J P Peyrat; M Deminatti; A Delobelle-Deroide; J Lefebvre
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

2.  The somatostatin analog Sandostatin (SMS201-995) in treatment of DMBA-induced rat mammary tumors.

Authors:  G H Bakker; B Setyono-Han; J A Foekens; H Portengen; W L van Putten; F H de Jong; S W Lamberts; J C Reubi; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1990-11       Impact factor: 4.872

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.